Keywords: DBV Technologies, Viaskin, Peanut allergy, Immunotherapy

Positive interim clinical data in allergic children treated with Viaskin Peanut

Article | 19 June 2012

Print This

French allergy specialist DBV Technologies (Euronext: DBV), creator of Viaskin, a new standard in the treatment of allergy, says that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in